Across TCGA pan-cancer cohorts, SKIV2L RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated SKIV2L data layer compared with 6 for mutation status and 3 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher SKIV2L RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated SKIV2L expression acts as an unfavorable survival marker, although some lineages such as THYM and READ show a favorable association.
COAD, KIRC, and UVM are the cancer types where SKIV2L RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.